KNSA - Kiniksa Pharmaceuticals, Ltd.
| Previous Close | 13.86 |
| Open | 13.71 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's Range | 13.50 - 14.21 |
| 52 Week Range | 13.04 - 32.88 |
| Volume | 64,830 |
| Avg. Volume | 77,092 |
| Market Cap | 751.638M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.66 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.25 |
- GlobeNewswire•13 days ago
Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology
- Preclinical data support rationale for targeting GM-CSF in GCA – - Mavrilimumab shows biological effect on genes relevant to GCA pathophysiology in ex vivo cultures of GCA.
- Simply Wall St.•15 days ago
The Kiniksa Pharmaceuticals (NASDAQ:KNSA) Share Price Is Down 23% So Some Shareholders Are Getting Worried
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...
- GlobeNewswire•26 days ago
Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019
HAMILTON, Bermuda, May 30, 2019 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and.
- GlobeNewswire•27 days ago
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
HAMILTON, Bermuda, May 29, 2019 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the following investor conferences in June: Jefferies.
- GlobeNewswire•last month
Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, will present data from a systematic literature review highlighting the burden of illness and unmet medical needs associated with recurrent pericarditis at the International Society for the Pharmacoeconomic and Outcomes Research (ISPOR) in New Orleans, LA. “Recurrent pericarditis is a debilitating disease for patients who suffer from frequent flares,” said Raj Kannan, Chief Commercial Officer at Kiniksa.
- GlobeNewswire•last month
Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
HAMILTON, Bermuda, May 13, 2019 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and.
- GlobeNewswire•2 months ago
Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
– First patient dosed in Phase 2a trial of KPL-716 in prurigo nodularis– Upcoming presentations at SID, ISPOR and EULAR scientific conferences on KPL-716, rilonacept and.
- Insider Monkey•2 months ago
Is Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- MoneyShow•2 months ago
Long-Term "GameChangers" in Biotech
When I'm hunting for unicorns, I start with biotech. They won't all be winners. But in a well-constructed portfolio, enough of them will hit their commercial targets with sufficient force to make their shareholders very happy, explains Hilary Kramer, editor of GameChangers.
- GlobeNewswire•2 months ago
Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
HAMILTON, Bermuda, April 17, 2019 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and.
- GlobeNewswire•3 months ago
Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs
HAMILTON, Bermuda, April 08, 2019 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and.
- GlobeNewswire•3 months ago
Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session
- Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period- Enrollment is ongoing in RHAPSODY, Kiniksa’s pivotal Phase 3.
- GlobeNewswire•4 months ago
Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity
– Enrollment and dosing of patients commenced in rilonacept pivotal Phase 3 trial – Enrollment and dosing of patients commenced in mavrilimumab global Phase 2 trial – KPL-716.
- GlobeNewswire•4 months ago
Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference
HAMILTON, Bermuda, Feb. 28, 2019 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Cowen and Company 39th Annual Healthcare Conference.
- GlobeNewswire•4 months ago
Kiniksa Pharmaceuticals to Present at the Barclays Global Healthcare Conference
HAMILTON, Bermuda, Feb. 26, 2019 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Barclays Global Healthcare Conference on Tuesday,.
- GlobeNewswire•5 months ago
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering
Kiniksa Pharmaceuticals, Ltd. (KNSA) (“Kiniksa”, “we”, and “our”) announced today the pricing of its public offering of 2,654,984 Class A common shares at a public offering price of $18.26 per share, before underwriting discounts and commissions. In addition, Kiniksa has granted the underwriters a 30-day option to purchase up to 398,247 additional Class A common shares at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on February 4, 2019, subject to customary closing conditions.
- Benzinga•5 months ago
The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 28) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...
- GlobeNewswire•5 months ago
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement
Kiniksa Pharmaceuticals, Ltd. (KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of 8,000,000 Class A common shares. In addition, Kiniksa expects to grant the underwriters a 30-day option to purchase up to 1,200,000 additional Class A common shares. All of the Class A common shares are being offered by Kiniksa.
- GlobeNewswire•6 months ago
Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab
Kiniksa Pharmaceuticals, Ltd. (KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced an active investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for a clinical study of mavrilimumab in subjects with giant cell arteritis (GCA). U.S. subjects will be included in the ongoing, global Phase 2 clinical trial, in which dosing has already commenced in multiple countries.
- Zacks•6 months ago
5 Best-Performing IPOs of 2018
Strong economic fundamentals and increased foreign investment have led to such a high number of companies going public.
- GlobeNewswire•6 months ago
Kiniksa Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Dec. 17, 2018 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 37th Annual J.P. Morgan Healthcare Conference on.
- GlobeNewswire•6 months ago
Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial
Kiniksa Pharmaceuticals, Ltd. (KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced interim data from an open-label Phase 2 clinical trial of rilonacept, a weekly, subcutaneously-injected, recombinant fusion protein that blocks IL-1α and IL-1β signaling, in subjects with symptomatic recurrent pericarditis. The data show reductions in both inflammation and reported pain after the first dose which persisted throughout the treatment period.
- GlobeNewswire•7 months ago
Kiniksa Provides Update on U.S. FDA Review of Investigational New Drug Application for Mavrilimumab in Giant Cell Arteritis
Kiniksa Pharmaceuticals, Ltd. (KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline consisting of five product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions, today announced that the U.S. Food and Drug Administration (FDA) requested additional information regarding the delivery device to be used in the company’s Phase 2 clinical trial of mavrilimumab in giant cell arteritis. In light of its device-related information request, the FDA placed the company’s recently-submitted investigational new drug application (IND) on clinical hold.
- GlobeNewswire•7 months ago
Detailed Research: Economic Perspectives on Knight-Swift Transportation, Benitec Biopharma, Eastern, Kiniksa Pharmaceuticals, Qualstar, and Nomura Holdings Inc ADR — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•8 months ago
Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress
– Rilonacept pivotal Phase 3 clinical trial initiating this year– Mavrilimumab pre-IND meeting complete; plans for global Phase 2 clinical trial advancing– KPL-716 advancing.
